Ataraxis AI, a frontier laboratory developing artificial intelligence (AI)–powered prognostic tools for oncology, and MEDSIR (Medica Scientia Innovation Research), a global leader in oncology research, today announced a strategic collaboration to integrate artificial intelligence into multiple major international trials. These studies, involving data from more than 1,000 patients across randomized clinical trials, aim to identify biomarkers that can optimize treatment strategies for breast cancer, including therapies with CDK4/6 inhibitors and antibody-drug conjugates (ADCs).

MEDSIR has been a key contributor to oncology clinical trials, helping support the advancement of transformative therapies into standard practice. These efforts have expanded access to novel treatment options and improved outcomes for patients worldwide. The introduction of new therapeutics creates an opportunity but also a challenge to select the right drug for every patient. Ataraxis addresses this critical need with Ataraxis Breast, the first AI-native platform in breast cancer developed to predict patient outcomes and treatment effects. By integrating insights from standard digital pathology slides with clinical data, the platform provides a new evidence-based layer to support treatment decisions and personalize care.

Building upon Ataraxis' previous positive clinical validation results showing efficacy across major breast cancer subtypes, the research collaboration between MEDSIR and Ataraxis AI will focus on leveraging artificial intelligence to predict outcomes across key breast cancer subtypes—including HR+ and HER2+ cohorts—encompassing patients in early-stage and metastatic settings. The goal is to enhance clinical decision-making by integrating AI-driven insights into routine oncology workflows.

“Breast cancer treatment continues to improve, with new therapies becoming available every year. However, this creates a challenge in selecting the right drug at the right time. At Ataraxis, we are developing AI-native tools to accurately predict patient outcomes and treatment response for all cancer patients. We are proud to partner with MEDSIR to validate our breast cancer platform using data from practice-changing clinical trials,” said Jan Witowski, Chief Executive Officer and Co-Founder of Ataraxis AI.

“At MEDSIR, we are committed to accelerating innovation in oncology through collaborative research that brings real value to patients and clinicians,” said Alicia García, Scientific Director at MEDSIR. “Partnering with Ataraxis AI allows us to integrate cutting-edge artificial intelligence into clinical trials, generating evidence that can transform treatment decision-making in breast cancer. This collaboration represents an important step toward a future where precision oncology is not just a concept, but a standard of care.”

This announcement demonstrates the commitment to building global collaborative networks for both MEDSIR and Ataraxis AI. With strategic headquarters in Europe and the United States, MEDSIR has built an extensive global network of more than 600 researchers and has conducted 65 clinical trials across more than 200 sites in 14 countries. Ataraxis AI has partnerships with over 40 institutions on the development, validation, and deployment of AI-based tools for treatment selection. Additionally, this collaboration marks a milestone in building clinical evidence for Ataraxis Breast moving beyond retrospective observational studies and into prospective trials investigating new therapies.

About Ataraxis AI

Ataraxis is an AI precision medicine company transforming patient outcomes through the power of artificial intelligence. Its flagship platform, Ataraxis Breast, leverages digital pathology and clinical data to support personalized treatment decisions for patients with breast cancer and provides greater accuracy than standard of care genomic assays. To learn more, visit ataraxis.ai.

About MEDSIR

Established in 2012, MEDSIR prides itself on working closely with its strategic partners to drive innovation in oncology research. Operating in Spain and the United States, the company provides end-to-end clinical trial management, from study design to publication, with an extensive global network of experts and integrated technology to streamline the process. The company offers proof-of-concept support and a strategic approach that enables research partners to benefit from the best of both worlds: industry clinical research and investigator-driven trials.

With the aim of promoting independent research worldwide, MEDSIR has formed a strategic alliance with Oncoclínicas, the leading oncology group in Brazil, which offers outstanding research potential in South America. For further information: www.medsir.org

View source version on businesswire.com: https://www.businesswire.com/news/home/20251002282761/en/